Consumer Marketing briefs

Share this article:
Sanofi-Aventis US is partnering with the NBA, the WNBA and the NBA Development League, along with the American Diabetes Association, on a national multimedia program dubbed Dribble to Stop Diabetes. The campaign, which had its kick-off during the NBA All-Star 2011, will include a nationally broadcast PSA featuring Dwight Howard of the Orlando Magic, Alana Beard of the Washington Mystics and legends Walt Frazier and Chris Dudley.

An Ogilvy CommonHealth Worldwide global survey of 264 pharmaceutical executives in 57 countries found 74% planning increased spending on digital communications. The survey also found a trend toward greater customer segmentation and a changing role for patients.

Hologic launched a DTC campaign for its NovaSure endometrial ablation procedure for premenopausal women with heavy periods who don't want more kids. The voiceover for the broadcast ad says: “Women with very heavy periods can finally get back to life,” as a montage of images shows women being active. The campaign includes TV, magazine and online, leveraging paid advertising and social media.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?